BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240222T090000
DTEND;TZID=America/New_York:20240222T160000
DTSTAMP:20240202T211124Z
CREATED:20240202T210750Z
LAST-MODIFIED:20240202T211124Z
UID:59861-1708592400-1708617600@globalbiodefense.com
SUMMARY:PACCARB Public Meeting
DESCRIPTION:The 24th Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) public meeting will be held virtually on February 22\, 2024. \nThis will be the second of two meetings to address the task provided to the PACCARB by the Secretary of HHS to address antimicrobial resistance globally. The focus of the meeting will be on international implementers and the gaps\, challenges\, and opportunities they see to combat AMR globally – specifically focusing on low- and middle-income countries. \nMeetings of the PACCARB are open to the public\, and virtual meetings can be accessed through the webcast. Registration to attend is not required but is encouraged. Attendees may also directly address the council on topics of antimicrobial resistance during public meetings. To provide written comments\, please e-mail your comments to CARB@hhs.gov. Written comments must be sent in by midnight February 15\, 2024 and should be limited to no more than one page. All public comments received prior to the deadline will be provided to the PACCARB council members. \nMeeting times are tentative and subject to change. Please visit HHS’ PACCARB website for the most current information.
URL:https://globalbiodefense.com/event/paccarb-public-meeting/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240223
DTEND;VALUE=DATE:20240224
DTSTAMP:20240218T175243Z
CREATED:20240218T174811Z
LAST-MODIFIED:20240218T175243Z
UID:60021-1708646400-1708732799@globalbiodefense.com
SUMMARY:Rapid Access to Products in Development (RAPID) Virtual Industry Day
DESCRIPTION:A Joint Industry Day for the Rapid Access to Products in Development (RAPID) program to be held virtually on 23 Feb 2024. \nThe Joint Program Executive Office for Chemical\, Biological\, Radiological\, and Nuclear Defense\, Enabling Biotechnologies (JPEO-CBRND-EB)\, develops\, manufactures and delivers safe and effective Medical Countermeasures (MCMs) for preparedness\, prevention\, protection\, response\, and recovery from CBRN threats. \nThe Rapid Access to Products in Development (RAPID) program is an integrated defense system composed of both physical MCM storage and fielding capabilities and a readily accessible information warehouse and sharing system (the RAPID Database). \nThe purpose of this Industry Day is to identify industry partners and capabilities to develop a RAPID Database capable of storing and organizing complex data and information related to CBRN MCMs such that it is intuitively accessible by a variety of end users during urgent planning and response situations. \nThe Database is intended to provide actionable information to assist CCMD-level decision makers when evaluating a RAPID MCM for potential administration to US warfighters; and JPEO- and CBDP-level decision makers when determining portfolio investment strategies or rapid response adjustments based on changing circumstances. \nThis Industry Day will include presentation by JPL EB as well as opportunities for industry partners to present their capabilities in one-on-one breakout sessions with representatives from the Government agencies. Industry partners will update Government stakeholders\, partners\, and end users on current efforts and capabilities. \nCompanies that wish to attend must register no later than 19 Feb 2024. More information is available at SAM.gov Notice ID W911SR-24-S-RAPID.
URL:https://globalbiodefense.com/event/medical-countermeasures-rapid-access-to-products-in-development-rapid-virtual-industry-day/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240228
DTEND;VALUE=DATE:20240301
DTSTAMP:20240226T215053Z
CREATED:20240226T215042Z
LAST-MODIFIED:20240226T215053Z
UID:60125-1709078400-1709251199@globalbiodefense.com
SUMMARY:Meeting of the Advisory Committee on Immunization Practices (ACIP)
DESCRIPTION:The CDC’s Advisory Committee on Immunization Practices (ACIP) will convene 28-29 February 2024 in Atlanta\, GA and via webcast. \nThe ACIP develops recommendations for U.S. immunizations\, including ages when vaccines should be given\, number of doses\, time between doses\, and precautions and contraindications. \nThe agenda will include the following: \n\nUpdate on chikungunya vaccine licensure and review of proposed policy options for chikungunya vaccine use among U.S. adults traveling abroad\, laboratory workers\, and pregnant and breastfeeding persons\nGuidance to use Td vaccine for those instances when receipt of the pertussis component is contraindicated\nCOVID-19 vaccination coverage\, effectiveness and economic analysis of additional dose recommendations\nNext steps for the COVID-19 vaccine program\nInterim estimates of 2023-24 seasonal influenza vaccine effectiveness\nSafety of LAIV4 in children with asthma\nInfluenza B/Yamagata update\nPolio Work Group deliberations on potential use of nOPV2 as an outbreak control measure in the US\nClinical considerations for children who received fractional dose inactivated polio vaccine (fIPV) in other countries\nPost-marketing safety surveillance of older adult RSV vaccination\nPreliminary Analysis of Guillain-Barré Syndrome (GBS) following RSV vaccination among adults 65 years and older\nOverview of Moderna’s investigational RSV Vaccine (mRNA-1345) in adults ≥60 years of age\nRevising the adolescent Meningococcal vaccine schedule\nCurrent epidemiology of invasive pneumococcal disease and pneumococcal vaccine coverage in adults\nPreliminary findings of the Pneumococcal pNeumonia Epidemiology\, Urine serotyping\, and Mental Outcomes (PNEUMO) US study\nBackground on invasive Hib disease and vaccination among American Indian and Alaska Native Populations\n\nThe meeting will be held on February 28\, 2024\, from 8 a.m. to 5 p.m.\, EST and February 29\, 2024\, from 8 a.m.\nto 3 p.m.\, EST (times subject to change). \nPlease visit the CDC’s Advisory Committee on Immunization Practices for the latest information. No registration is required to watch the webcasts.
URL:https://globalbiodefense.com/event/meeting-of-the-advisory-committee-on-immunization-practices-acip/
CATEGORIES:Government Hosted
LOCATION:https://video.ibm.com/channel/VWBXKBR8af4
END:VEVENT
END:VCALENDAR